The distribution of Acacias.l. across Texas reflects a combination of ecological specialization, soil preferences, and historical biogeographic processes. Species richness is highest in the Rio Grande Plains and South Texas brushlands, where thornscrub communities are dominated by V. farnesiana, S. berlandieri, and A. schaffneri. These species occupy calcareous soils, rocky slopes, and disturbed rangelands, often forming dense thickets that provide critical forage and wildlife cover [4][6]-[10]. In West Texas, S. greggii and V. constricta are characteristic of arroyos, gravel washes, and canyon systems in the Big Bend and Trans-Pecos regions. Their distributions are shaped by episodic water availability, coarse substrates, and extreme temperature fluctuations [10]-[12]. More geographically restricted taxa, such as V. schottii and V. vernicosa, occur primarily on limestone outcrops and in desert foothills, reflecting adaptations to xeric conditions and shallow, alkaline soils [10][12][13].

Several species demonstrate broad ecological tolerance. V. farnesiana extends into central counties, thriving in heavy clay soils and highly disturbed environments such as roadsides and pastures [4][6][7][14]. Acaciellaangustissima occupies sandy loams and upland prairies, providing forage for livestock and wildlife, although mild toxicity has been documented at high intake levels [6][7][15][16]. Naturalized species—including A. dealbata and A. stenophylla—are confined mainly to horticultural plantings and disturbed urban landscapes in Central Texas, underscoring the role of human-mediated introduction in shaping local floristic composition [6][10][17][18].

Collectively, the Texas Acacia flora spans semi-arid thornscrub, desert canyons, riparian corridors, and upland prairies. This ecological breadth underscores their importance in rangeland dynamics, wildlife habitat, and ethnobotanical traditions, while also revealing gaps in systematic ecological and pharmacological research.

Synonymy. Several species historically classified under Acacia have been reassigned to segregate genera, including A. farnesiana → V. farnesiana and A. greggii → S. greggii [19][20].

FamilyandSubfamily. All Texas species belong to the subfamily Mimosoideae within the family Fabaceae.

DiagnosticTraits. Shared morphological features include bipinnate leaves, stipular spines (especially prominent in Vachellia), glandular nodes at the petiole base, and distinctive inflorescence types—globose heads (e.g., V. farnesiana) versus spicate forms (e.g., S. wrightii) [19][21]. These taxonomic distinctions underpin ecological interactions, phytochemical variation, and traditional uses.

Evidence for antimicrobial, antioxidant, and anti-inflammatory activity in Texas Acacias.l. is derived predominantly from in vitro assays and animal-based models, with no corresponding human clinical data to date. A subset of Texas Acacias.l. has demonstrated compelling pharmacological properties, producing secondary metabolites with antimicrobial, antioxidant, anti-inflammatory, and enzyme-modulatory activities. Extracts from V. farnesiana pods exhibit strong vibriocidal activity against Vibriocholerae, attributed to methyl gallate, and show anti-inflammatory effects in vivo [34]. Leaves of V. rigidula exhibit potent antioxidant activity and are effective against resistant bacterial strains [24][29]. Additional studies on V. farnesiana bark further support its antioxidant and anti-inflammatory potential [35]. Together, these findings indicate promising bioactivity but remain confined to preclinical experimental systems.

Evidence supporting metabolic and neurological effects is based largely on in vitro enzyme inhibition studies and controlled rodent models, with no validation in human subjects. Several species have been investigated for potential roles in metabolic and neurological disorders. Acaciellaangustissima pod extracts reduce hyperglycemia and oxidative stress in diabetic rats, partially through modulation of α-amylase, α-glucosidase, and angiotensin converting enzyme activity [36]. Phenolic compounds from Acaciadealbata inhibit enzymes associated with cognitive decline and glucose metabolism, with effects demonstrated in vitro and supported by mechanistic animal studies [26][37]. These results are comparable to the hypoglycemic, anti-inflammatory, and neuroprotective properties of the non-Texas-native V. nilotica [37]. Diterpenoids from Acaciaschaffneri roots exhibit selective cytotoxicity against cancer cell lines in vitro, underscoring their pharmacological promise, though this remains preliminary [28]. Collectively, these results suggest therapeutic relevance but warrant cautious interpretation in the absence of translational or clinical validation.

Current toxicological understanding is derived from phytochemical isolation studies, livestock observations, and ethnoveterinary reports, rather than standardized toxicology trials. In particular, phenethylamine alkaloids identified in Senegaliaberlandieri and Vachelliarigidula are consistently associated with adverse neurological effects in grazing animals, including locomotor ataxia and the “limber leg” syndrome documented in livestock systems [28][32][38]. These effects are supported by both alkaloid characterization studies and field observations, thereby establishing a clear toxicological risk under conditions of uncontrolled exposure.

Importantly, these documented livestock toxicities are not indicators of therapeutic potential but rather reflect dose-, route-, and species-specific sensitivities in real-world grazing contexts. From a pharmacological perspective, phenethylamine alkaloids remain of interest because they interact with central nervous system pathways and monoaminergic signaling, mechanisms relevant to the stimulant, neuroactive, and enzyme-modulating effects observed in related compound classes. Consequently, their presence signals bioactivity rather than inherent therapeutic suitability.

Ethnoveterinary reports further highlight this duality, describing traditional medicinal or functional uses of these taxa alongside explicit recognition of toxicity risks, particularly in animal husbandry contexts [39]. However, the absence of standardized dose-response data, controlled toxicological studies, and long-term safety assessments prevents meaningful separation of pharmacologically relevant activity from hazardous exposure. Resolving this distinction remains a critical research gap, particularly for taxa containing phenethylamine alkaloids, where therapeutic exploration must proceed in parallel with rigorous safety evaluation.

The broader pharmacological literature on Texas Acacias.l. remains largely preclinical and exploratory, with uneven species coverage and limited methodological standardization. Despite promising early findings, only V. farnesiana and V. rigidula have been evaluated across multiple biological endpoints [24][30][34]. Many Texas species—including V. texana, V. constricta, V. shrevei, V. schottii, S. wrightii, Acaciellaleucothrix, Acaciellasuffrutescens, and Acaciellaroemeriana—lack modern bioactivity studies beyond preliminary chemical screening [19]. No clinical trials exist, and few investigations employ dose-standardized extracts, limiting reproducibility and cross-study comparison [21]. Toxicological assessments of phenethylamine alkaloids remain particularly underdeveloped, leaving critical gaps in safety evaluation and risk-benefit interpretation [28][32][38].

This review, therefore, synthesizes and critically evaluates experimental studies on the pharmacological properties of the 17 Acacias.l. in Texas. By integrating ethnobotanical knowledge with phytochemical and bioassay evidence, it aims to: 1) Summarize current findings across antioxidant, antimicrobial, antiinflammatory, metabolic, cytotoxic, and other biological activities; 2) Identify underexplored species and metabolite classes; 3) Propose strategic research priorities, including compound isolation, HPLCbased phytochemical standardization, advanced invivo models, and sustainability considerations. These efforts seek to advance Texas Acacia species toward safe, evidence-based therapeutic development while balancing ecological and toxicological concerns.

While pharmacological findings highlight promising avenues for therapeutic development, they represent only one dimension of Acacias.l.’s broader significance in Texas. Understanding the full therapeutic landscape of these species requires situating modern bioactivity research within the long-standing cultural and medicinal traditions that guided their use. The following section, therefore, examines the ethnobotanical knowledge and traditional practices associated with Texas Acacias.l., providing essential context for interpreting their contemporary pharmacological relevance.

Ethnomedical practices involving Texas Acacias.l. are closely tied to ecological distribution and cultural accessibility (Table 2). Remedies prepared from bark, leaves, pods, flowers, and gum are used to address a broad spectrum of ailments, including gastrointestinal disorders, respiratory infections, skin conditions, inflammation, and fever [8][31][40].

Table 2. Notable ethnomedicinal reports by species.

Collectively, the ethnobotanical record of Texas Acacias.l. reflects a profound interplay between cultural heritage, ecological familiarity, and medicinal innovation. Traditional uses—from respiratory relief with S. wrightii to antimicrobial applications of V. farnesiana—offer valuable leads for pharmacological exploration. Yet systematic validation remains limited. Few species have been rigorously evaluated in controlled bioassays or toxicological studies, and many reported uses lack corroborating experimental evidence [8][31][32][40]. This gap underscores the need for targeted research to determine whether traditional practices align with measurable biological activities.

Although ethnobotanical records provide valuable insight into traditional applications, validating these uses requires a detailed understanding of the chemical constituents responsible for biological activity. The following section, therefore, examines the phytochemistry of Texas Acacia species, highlighting the metabolite classes and analytical methods that underpin modern pharmacological investigations.

Texas Acacias.l. exhibit remarkable chemical diversity, reflecting their broad phylogenetic distribution across Vachellia, Senegalia, Acacia, and Acaciella. Although these taxa share several major classes of secondary metabolites—including phenolics, flavonoids, alkaloids, terpenoids, sterols, and fatty acids—the specific compounds and their relative abundances vary substantially among species. Table 3 summarizes the principal metabolites reported to date, highlighting both the breadth of chemical diversity and the uneven availability of phytochemical data across taxa.

Table 3. Species-specific phytochemical profiles of Texas Acacia.

Within the Texas flora, the Acacia and Acaciella lineages introduce additional layers of chemical variation that complement the profiles observed in Vachellia and Senegalia. Acaciadealbata, although nonnative, provides a useful comparative context through its production of flavonols, chalcones, and seed fatty acids such as linoleic and oleic acid [21][44]. Acaciaschaffneri is notable for its phyllocladanetype diterpenoids, including phyllocladan-16α,19-diol and related structures [28][46].

In contrast, Acaciella species—though fewer in number—exhibit some of the broadest metabolite repertoires reported within the group. Their profiles combine phenolics, alkaloids, sterols, and distinctive non-protein amino acids, underscoring their biochemical distinctiveness. Acaciellaangustissima is particularly well studied and contains phenolic acids, condensed tannins, N-methyl β-phenethylamine (NMPEA), tyramine, sterols, triterpenes, fatty acids, and rare non-protein amino acids [19][25][33][36]. Acaciaroemeriana has a more limited profile, with confirmed production of tyramine and other simple phenethylamines [19][33][47].

Moving from the chemically broad Acaciella lineage to the more alkaloid-focused Senegalia, a distinct shift in phytochemical emphasis becomes evident. S. berlandieri contains one of the broadest alkaloid spectra documented in the group, including tyramine, NMPEA, hordenine, nicotine, nornicotine, mescaline, and several amphetaminelike compounds [29][32]. S. greggii synthesizes tyramine and related amines and is one of the few Texas taxa with confirmed production of the flavonol fisetin [19][33][47].

In contrast to the alkaloid-dominated profiles of Senegalia, the genus Vachellia encompasses some of the most chemically diverse and extensively characterized taxa within Texas Acacia. V. farnesiana possesses one of the most complex phytochemical profiles, producing methyl gallate, gallic acid, naringenin, multiple galloyl glucose derivatives, and triterpenoids such as α-amyrin, β-amyrin, lupeol, and β-sitosterol, along with numerous volatile floral constituents [27][43][48][49]. V. rigidula similarly exhibits high chemical diversity, synthesizing NMPEA, phenolic acids, diterpenes, and volatile compounds including jasmone and panisaldehyde [24][30][34][43]. Related species such as V. constricta, V. schottii, and V. texana possess simpler alkaloid-rich profiles dominated by NMPEA and cyanogenic or other amine-based metabolites [18][19][33].

The phytochemical characterization of Texas Acaciasensu lato species relies on a suite of extraction and analytical techniques that vary widely in resolution, sensitivity, and application.

HPLCandLC–MS/MS are widely used for quantifying phenolic acids and flavonoids [30][49].GC–MS is essential for analyzing alkaloids and volatile terpenoids, particularly in V. rigidula and S. berlandieri [28][32].TLCandUV–visspectrophotometry remain common for rapid qualitative screening [19][24].NMRandFT–IR, though underutilized, are critical for structural elucidation and should be expanded in future work [19][30][44].

Despite the growing body of phytochemical research on Texas Acaciasensu lato, substantial methodological and data-driven limitations continue to constrain comparative analyses and biological interpretation. Key challenges include:

Extraction protocols lack standardization.Metadata on plant maturity, seasonality, and habitat are often missing.Fewer than half of Texas species have been chemically profiled.Most studies provide qualitative rather than quantitative data.Advanced structural tools (NMR, HRMS) remain underused.

Recent global reviews emphasize the need for metabolomics-driven, standardized phytochemical workflows to improve reproducibility and enable meaningful cross-species comparisons [42][43]. Within this context, phytochemical profiles provide an essential foundation for interpreting the biological activities attributed to Texas Acacias.l. Building on this chemical framework, the following section links metabolite diversity to therapeutic relevance by synthesizing current pharmacological evidence, with emphasis on antimicrobial, anti-inflammatory, metabolic, neuroactive, and cytotoxic properties documented across regional taxa.

Extracts of V. farnesiana pods demonstrate strong vibriocidal activity against Vibriocholerae, attributed to methyl gallate, and exhibit notable anti-inflammatory effects in vivo [41]. Leaves of V. rigidula show potent antioxidant activity, achieving up to 70% inhibition of lipid peroxidation, and have been shown to combat resistant bacterial strains [22][28].

Acaciellaangustissima exhibits antidiabetic and hypolipidemic effects through modulation of α-amylase, α-glucosidase, and ACE activity [36]. A. dealbata demonstrates enzymeinhibitory activity relevant to cognitive decline and glucose metabolism [26][37].

Diterpenoids from Acaciaschaffneri roots exhibit selective cytotoxicity against cancer cell lines [28]. Phenethylamine alkaloids in Senegaliaberlandieri and Vachelliarigidula have documented neuroactive effects, including locomotor ataxia in livestock, and warrant further investigation for CNS-related pharmacology [30][32]. Recent pharmacological reviews emphasize the need to explore neuroprotective and anticancer activities across Acacias.l., including Texas taxa [45][50].

Although several Texas Acaciasensu lato species show promising pharmacological potential, the current evidence base remains fragmented and methodologically limited. To date, only a small subset of species has been evaluated across multiple biological endpoints, and most studies rely heavily on in vitro assays without corresponding in vivo validation. Critical data on toxicity, dose–response relationships, and pharmacokinetics remain scarce, and no clinical trials have been conducted for any Texas species. Recent global studies further emphasize the need to integrate metabolomics, standardized bioassays, in vivo disease models, and comprehensive toxicity testing to advance Acaciabased therapeutics [44][50].

Collectively, these gaps underscore the scientific and methodological challenges that continue to constrain the reliability, reproducibility, and translational potential of current findings. The following section expands on these limitations and outlines the key research priorities necessary to strengthen future pharmacological investigations.

Although at least 17 Acacias.l. species occur in Texas across Vachellia, Senegalia, Acaciella, and Acacia s.s.; fewer than half have undergone modern phytochemical or pharmacological evaluation. Research disproportionately focuses on V. farnesiana, S. berlandieri, S. greggii, and Acaciellaangustissima [19][25][26][30][49]. In contrast, species such as V. texana, Acaciellaroemeriana, A. schaffneri, and A. leucothrix remain largely uncharacterized. Recent global analyses of Acacia diversity [44][45] reinforce the importance of expanding species coverage to avoid overlooking taxa with significant therapeutic potential.

Methodological variability is a major barrier to reproducibility. Extraction protocols differ widely in solvent polarity, temperature, duration, and plant preparation—all factors that significantly influence metabolite yield and composition [24][27][30][32]. No standardized method exists for extracting total phenolic acids from Acacia tissues [24], and solvent polarity strongly affects phenolic solubility [30].

Recent metabolomics-driven studies [44][45] emphasize the need for standardized extraction and analytical workflows to enable cross-species comparisons. In addition, most Texas studies rely on crude ethanolic or aqueous extracts and rarely proceed to fractionation or structural elucidation [30]. Advanced analytical tools such as LC–MS/MS, GC–MS, NMR, and HRMS—now widely recommended in global Acacia research [44][45][51]—remain underutilized.

A major limitation is the scarcity of toxicity and dose–response data. Many studies report biological activity without determining IC₅₀, MIC, LD₅₀, or therapeutic index values [23][30]. Most investigations rely exclusively on in vitro assays—particularly antioxidant and antimicrobial screens [19][23][24]—which do not account for bioavailability, metabolism, or systemic toxicity [25][51].

Only a few studies have evaluated acute toxicity or safe dosage ranges, such as those involving S. greggii seed extracts [42][47]. Limited in vivo work exists, primarily focusing on anti-inflammatory or hepatoprotective effects [27][36][42]. Recent pharmacological reviews [50][51] emphasize the need for robust in vivo and toxicological studies before any Acaciaderived product can advance toward clinical evaluation.

A persistent gap persists between traditional uses and modern scientific validation. Species such as V. texana and Acaciellaroemeriana are used in Indigenous and Mexican-American communities to treat respiratory disorders and fever [8][23][33], yet no contemporary pharmacological studies have substantiated these applications. Recent ethnopharmacological reviews [50][51] underscore the global importance of aligning traditional knowledge with laboratory validation—an approach urgently needed for Texas species.

Phytochemical composition is strongly influenced by ecological factors, including soil type, water stress, seasonality, and plant age. However, most studies provide minimal metadata on collection sites, phenological stage, or habitat characteristics [24][26][27][30][32][42]. Metabolomics studies [43] emphasize the importance of ecological metadata for interpreting chemotypic variation.

Current research on Texas Acacias.l. is constrained by:

1) Underrepresentation of species—more than half remain unstudied.

2) Non-standardized phytochemical methods—limited use of advanced metabolomics tools.

3) Absence of clinical data—no human studies exist.

4) Weak pharmacological rigor—few dose–response or in vivo evaluations.

5) Poor alignment with ethnobotanical knowledge—traditional uses often lack empirical support.

6) Insufficient ecological metadata—environmental influences on chemistry are rarely documented.

Recent global reviews [44][45][50] underscore the urgency of addressing these limitations to advance Acaciabased therapeutics. Addressing these gaps will require a coordinated, multidisciplinary research strategy that integrates standardized phytochemical workflows, rigorous pharmacological testing, comprehensive toxicological assessment, and more substantial alignment with ethnobotanical knowledge. Building on the constraints outlined above, the following section proposes future research directions to strengthen phytochemical characterization, enhance pharmacological validation, and improve the translational potential of Texas Acacia species.

Several understudied species—such as Acaciellaroemeriana, Acacialeucothrix, and Vachelliavernicosa—lack contemporary chemical data despite documented traditional uses [26]. Future work should:

Apply untargeted metabolomics (LC–MS/MS, NMR) to generate high-resolution chemical fingerprints [44][45].Use HPLC fingerprinting to standardize extract profiles and enable crossstudy comparisons.Prioritize isolation and structural elucidation of active compounds in species showing promising activity [19][20][27][30].

Recent reviews [45][51] highlight metabolomics-driven workflows as essential for advancing Acacia research globally. Building on this chemical foundation, broader pharmacological screening is also needed.

Most Texas Acacia studies focus on antioxidant or antimicrobial assays. Future research should:

Incorporate in vivo disease models to evaluate anti-inflammatory, antidiabetic, hepatoprotective, and analgesic effects [27][30].Expand testing to include anticancer (HCT116, MCF7), neuroprotective, antiviral, and immunomodulatory assays [45][50].Investigate CNSactive species such as S. berlandieri and V. rigidula, given their phenethylamine alkaloid profiles [30]-[32].

Global pharmacological reviews [46][50] strongly support expanding the pharmacological scope of Acacia research. Such expansion should be complemented by deeper engagement with ethnopharmacological knowledge.

Ethnopharmacological approaches remain underutilized. Future studies should:

Conduct ethnobotanical surveys in South and West Texas to document undocumented uses and preparation methods [31][48].Collaborate with community healers and herbalists to ensure culturally grounded research.Develop biocultural maps linking traditional use frequency with species distribution.

Recent reviews [47] highlight the global importance of aligning ethnobotanical knowledge with laboratory validation. Improved methodological consistency will further strengthen these efforts.

Future studies should:

Standardize solvent polarity, extraction duration, temperature, and plant preparation.Report on harvest location, plant maturity, phenological stage, and seasonal conditions [27][38][46][49].Include dose–response analyses with appropriate controls.

Recent metabolomics studies [45] emphasize the importance of methodological standardization. Such rigor is essential for translational and preclinical advancement.

To progress toward therapeutic applications, future research must incorporate:

Acute, subchronic, and chronic toxicity studies.Pharmacokinetic and bioavailability assessments.Synergy testing with standard drugs (e.g., NSAIDs).Formulation science to improve solubility and stability [19][27].

Recent pharmacological reviews [50][51] emphasize these steps as prerequisites for clinical translation. A structured research pipeline can help guide this progression.

A structured research pipeline is proposed:

1) Ethnobotanical Surveys.

2) Phytochemical Screening (LC–MS/MS, HPLC, NMR).

3) Bioactivity Testing (in vitro + in vivo).

4) Toxicological Evaluation.

5) Preclinical and Clinical Preparation.

This evidence-based framework aligns with global recommendations for advancing Acacia-derived therapeutics [44][45][50][51]. Collectively, these recommendations provide a roadmap for elevating Texas Acacias.l. from underexplored native plants to rigorously studied therapeutic candidates. The concluding section synthesizes these insights, emphasizing their broader significance for pharmacology, ethnobotany, and regional biodiversity.